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Of the various drugs in each of the three major
groups of bactericidal antibiotics, the amino-
glycosides regularly carry some risk of producing
nephrotoxic side effects [1]. Of the approximately
two dozen penicillins developed [2], so far only one
(guanylureidopenicillin, BL-P1654) has recognized
nephrotoxicity [31. This drug has not been released
for general use.
Most of the cephalosporins are also not obviously
nephrotoxic [1, 4, 5]. The production, however, of
acute proximal tubular necrosis by therapeutic-
range doses of cephaloridine [6], the second drug
developed in this group, and by very large doses of
the newer cephalosporins cefazolin [7] and cefa-
mandole [8] has caused concern about the ceph-
alosporins in general [4, 9—11]. This concern is influ-
enced by the fact that the aminoglycosides and the
cephalosporins are commonly used in combination.
The consistent risk of toxicity from any drug in the
former group makes a further risk from one in the
latter group extremely undesirable.
Studies in this laboratory have been mainly con-
cerned with the cephalosporins. Our interest in this
group of drugs was brought about by some unusual
properties of cephaloridine. This antibiotic stands
in sharp contrast to various other cephalosporins [5]
and to the structurally related penicillins [2] in un-
dergoing little or no net secretion by the mammalian
kidney [12-14]. Cephaloridine is, however, highly
cytotoxic to the proximal renal tubule [6, 12—15],
the segment of the nephron responsible for the se-
cretion of organic anions [16], including para-am-
minohippurate (PAH), as well as the various pen-
icillin and cephalosporin antibiotics [2, 5, 17]. The
cytotoxicity of cephaloridine is completely pre-
vented by probenecid [14, 18, 19] and several other
inhibitors of organic anion transport [14, 20], in-
cluding the nearly nontoxic [21] cephalosporin
cephalothin [22].
591
Transport and toxicity of cephaloridine
Our earliest studies were directed at (1) demon-
strating the existence of an unusual transport pro-
cess, reflected by a substantial degree of cortical
cephaloridine uptake with little or no net secretion,
(2) determining the extent of the relationship be-
tween this active transport process and the nephro-
toxicity of cephaloridine, and (3) defining the cellu-
lar mechanism of cephaloridine transport in the
proximal tubule.
Evidence for active transport. Studies of ceph-
aloridine transport began with the examination of
its uptake by the in situ kidney cortex. The cortex-
to-serum concentration ratio (C/S cephaloridine)
was found to be 12.2 (sEM) 0.8 in rabbits given a
mildly toxic dose of 100 mg/kg, s.c., of the drug 30
minutes before sacrifice [18]. The C/S ratio in ani-
mals receiving 25 mg/kg of the drug in similar pro-
tocols [18] or 30 mg/kg by constant infusion over 1
hour [23] were essentially the same.
These C/S cephaloridine ratios are twice as high
as C/S PAH ratios [23] and are eight times C/S
inulin (1.5 0.2) in the same animals [18, 23]. C/S
cephaloridine is reduced to levels slightly below C/S
inulin by probenecid, benzylpenicillin, and PAH
[18, 20, 23]. Further, the in vitro cortical slice-to-
medium ratio of cephaloridine is significantly re-
duced by anoxia [23]. Thus, despite the absence of
substantial net secretion of cephaloridine into the
urine, there is strong evidence for its active trans-
port in the proximal tubule by an organic anion se-
cretory carrier, probably that which transports
PAH into the cell at the antiluminal membrane [17,
23—25].
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Relationship to toxicity. C/S cephaloridine was
measured in various mammalian species with and
without the prior administration of probenecid.
Cortical uptake was found in the rabbit, the guinea
pig, and the rat in proportion to the toxicity of the
antibiotic to those species [10]. In further studies of
rabbits and guinea pigs treated with fully toxic
doses of the antibiotic, quantities of probenecid or
PAH that failed to maintain the concentration of
cephaloridine in renal cortex below 2000 gIg of wet
tissue weight did not substantially reduce proximal
tubular necrosis, whereas those that maintained the
concentration below 1000 ig/g were associated with
almost no cell necrosis (Table 1) [19, 20]. This con-
centration range fits with the 1839 148 jiglg re-
sulting from a 50% nephrotoxic dose of cephaloridine
in the rabbit [18].
Mechanism of transport. Two possible mecha-
nisms were considered that could account for this
occurrence of carrier-mediated uptake without sig-
nificant net secretion: (1) active secretion into the
proximal tubular fluid with an equal rate of reab-
sorption, and (2) active transport into the proximal
tubular cell at the antiluminal side with limited sub-
sequent movement into the tubular fluid.
Several lines of evidence have been developed
[18, 23, 25] against the former and in support of the
latter of these two proposed mechanisms. This in-
formation has been recently reviewed in some detail
[11] and will not be repeated in the present dis-
cussion. The cortical content of cephaloridine
therefore appears to represent, in large part, a rela-
tively trapped cellular pool (Fig. 1), which is larger
than that of PAH [23, 25], other cephalosporins [26,
27], and a variety of other antibiotics except the
aminoglycosides [26, 27]. We have found no evi-
dence of passive binding of cephaloridine in the
anoxic cortical slice [23] or in homogenates of renal
cortex. Instead, the high cortical cephaloridine con-
centrations appear to be the result of the hypothe-
sized limitation of movement from cell-to-luminal
fluid following active transport at the antiluminal
side [25].
Other cephalosporins
Cefazolin, one of the newer cephalosporins, is al-
so slightly nephrotoxic to the rabbit, but only in
doses ten times greater than those of cephaloridine
Table 1. Dose-responsiveness of the guinea pig to the effects of probenecidon cephaloridine transport and toxicity
Proximal tubular necrosis'
Probenecid
dose
mg/kg
Cortical cephaloridinea, g/g no. of animals
None Mild Moderate Severe0.5 houre 3 hourse
0 3123 63(6) 3576 148 (6) 1 0 4 7
5 2068 73 (6) 1940 91(6) 0 2 4 6
10 1403 134 (6) 1263 132 (6) 6 5 1 0
20 882 64 (6) 589 44 (6) 11 1 0 0
40 — 478 26 (6) 12 0 0 0
a Results are the means SEM, with the numbers of animals given in parentheses. Data are from Ref. 19.
Scored with randomly assorted coded slides [19]
Cephaloridine, 400 mg/kg, s.c., was given 0.5 hour after s.c. probenecid. Sacrifice was at 0.5 and 3 hours after injection of cephalori-
dine.
PAH (cephalothin) Cephaloridine
A B
Fig. 1. Schematic representation of the proximal tubular trans-
port and intrarenal distribution of para-aminohippurate (PAH)
and cephaloridine in the rabbit kidney: A PAH being excreted by
filtration and a greater degree of tubular secretion. Cortical
PAH includes large intracellular and intraluminal components;
medullary PAH includes filtered (approximately 25%) and se-
creted (75%) fractions. Both cortical and medullary PAH con-
centrations are reduced by probenecid. Cephalothin is secreted
similarly to PAH and is assumed to undergo the same easy efflux
from tubular cell-to-luminal fluid. Cortical cephalothin concen-
trations are in keeping with this hypothesis [26, 27]. B Cephalori-
dine being principally excreted by glomerular filtration, but
being also actively transported into proximal tubular cells with
little or no subsequent movement from cell-to-luminaifluid. Cor-
tical cephaloridine is made up of a large intracellular and a small
intraluminal fraction; medullary cephaloridine is derived princi-
pally from the glomerular filtrate. Cortical cephaloridine concen-
trations are greatly reduced by probenecid; medullary concentra-
tions are not reduced by transport inhibition. Detailed studies of
transport kinetics are found in Refs. 17 and 25 and are reviewed
in Ref. 11. Figure is modified from Tune [10].
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[7]. Cefazolin is secreted by the kidney [5]. Renal
cortical cefazolin concentrations are higher, how-
ever, than those of cephalothin (the least toxic of
these three cephalosporins [7, 21]) and lower than
those of cephaloridine (the most toxic of the three
[7, 21]) [27]. As in the case of cephaloridine [10, 28],
susceptibility to cefazolin toxicity increases in the
newborn rabbit with maturation of the organic an-
ion transport system [24], and cefazolin toxicity is
prevented by probenecid [10].
Because of these similarities between cephalori-
dine and cefazolin, we hypothesized that the vari-
ous cephalosporins may share the potential for pro-
ducing cytotoxicity in proportion to their intra-
cellular concentrations [10]. The singular property
of cephaloridine, which appeared to be responsible
for its notable degree of toxicity, was its unusual
renal transport and the resulting high local concen-
trations. Cephaloridine is toxic to other cell types,
such as fibroblasts and HeLa cells in culture, but
only at constant concentrations of 1000 tg/ml or
greater [29]. It remains to be determined what other
factors participate in the toxicity of the various
cephalosporins. The relationship between transport
and toxicity, however, is fundamental and is quan-
titatively impressive with cephaloridine [10, 19, 20].
Molecular basis of toxicity
The exact mechanism of cephalosporin toxicity
remains to be determined. The ultrastructural lesion
produced by cephaloridine influenced our initial
studies of this question.
Electron microscopic examination of the proxi-
mal tubular cell from 1 to 5 hours after the injection
of cephaloridine shows a progressive focal loss of
brush border, an increase in the number of apical
cell vacuoles, an increase in the number and com-
plexity of membranous structures in the apex of the
cell, occasionally in the form of whorls, a loss of
normal basolateral cell interdigitations, and a
rounded appearance of the mitochondria [15]. Al-
though the ultrastructural changes in mitochondria
could be the result of a loss of their normal vertical
orientation, there appears to be extensive alteration
of membranous structures within the damaged cell.
The mitochondrion was attractive for preliminary
study as an isolatable membranous organelle in
which one could examine the effects of the ceph-
alosporins on a series of processes critical to cell
metabolism. Studies were therefore begun in this
system. Protocols using renal cortical mitochondria
and tubule suspensions were designed to study the
possibility that the effects of cephalosporins on iso-
lated mitochondria might have a role in the patho-
genesis of cell injury.
Renal cortical mitochondria. The effects of ceph-
aloridine on respiration by rabbit renal cortical
mitochondria were examined under two conditions:
(1) in vitro exposure: respiration studied before and
after exposure of isolated mitochondria to the anti-
biotic; (2) in vivo exposure: respiration studied in
mitochondria isolated from animals that received
the antibiotic prior to sacrifice, compared with the
same functions in preparations from untreated
paired control animals.
Renal cortical mitochondria were isolated and
studied by methods previously described in detail
[30]. Respiration was studied with each of three
substrate groups: (I) glutamate plus malate, (2) suc-
cinate, and (3) the artificial electron donors tetra-
methylphenylenediamine (TMPD) plus ascorbate,
which allow a measure of cytochrome c oxidase ac-
tivity [31]. The respiratory control ratio (RCR),
which is the ratio of the higher rate of respiration
seen in the presence of ADP (state 3) to the lower
rate seen after the consumption of ADP (state 4),
provides a functional measure of the intactness of
these mitochondria, and presumably of their ability
to generate ATP [32, 33].
Previously published measurements of the effects
of cephaloridine on cortical mitochondria are
shown in Table 2 [30]. In in vitro studies, separate
aliquots of normal isolated mitochondria were used
for study with each of the three substrate groups,
and measurements were made before and after the
addition of 2000 pg/ml of cephaloridine to the res-
Table 2. Effects of cephaloridine on respiration
of rabbit renal cortical mitochondriaa
Substrate
Experimental!control, %
State3rate RCR
In vitro (2000 g/ml)
Glutamate-malate 64 66 6
Succinate 25 6 39 ie
TMPD-ascorbate 89 3b
In vivo (200 mg/kg)
Glutamate-malate 85 11 78 5
Succinate 58 5 69 5
TMPD-ascorbate 78 5h
Transient in vitro exposure
Glutamate-malate 57 13" 92 25
Succinate 69 19 82 14
TMPD-ascorbate 122 26 —
a Data are from Ref. 30. Results are means SEM (N = 6 in the
in vitro and the in vivo groups; N = 5 in the transient in vitro
group). RCR is respiratory control ratio. TMPD is tetramethyl-
phenylenediamine.
P < 0.05 vs. 100%.
P < 0.005 vs. 100%.
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piratory chamber. Because TMPD and ascorbate do
not provide a polarographic measure of phosphory-
lation, the observed rate of respiration with these
substrates is not an actual state 3 rate [31].
This concentration of 2000 g/ml of cephaloridine
is equal to that found in renal cortex under condi-
tions in which significant cell necrosis is seen [18,
19]. It reduces state 3 rates and RCR's with the nat-
ural substrates, as well as respiration with TMPD
plus ascorbate. The effect is most striking with suc-
cinate, with which the response to ADP is immedi-
ately and completely inhibited. Further in vitro
studies with one third of this concentration of ceph-
aloridine show a significant but significantly lower
reduction of the state 3 rate and the respiratory con-
trol ratio with succinate [30].
In studies of in vivo exposure, also shown in
Table 2, 200 mg/kg of cephaloridine was injected
s.c. into rabbits 2 hours before sacrifice for isolation
of the mitochondria [30]. The toxicity of cephalori-
dine to cortical mitochondria measured by this
method is qualitatively the same, although less se-
vere, than is that seen after in vitro exposure. The
most striking effect is a reduction of ADP-depen-
dent respiration with succinate as substrate.
Reversibility of the in vitro effect. The lower de-
gree of measured toxicity of cephaloridine to mito-
chondria exposed in vivo by administration of a tox-
ic dose before sacrifice, compared with that seen
after in vitro exposure of normal isolated mito-
chondria, raised the question of reversibility of the
in vivo toxic effect during the process of isolation
and washing.
In an effort to examine this possibility, we added
2000 .tg/ml of cephaloridine to one half of an initial
cortical homogenate prepared for isolation of mito-
chondria from untreated rabbits. The other half of
the homogenate, to which the saline diluent was
added, was used to prepare a paired, untreated con-
trol suspension. The subsequent centrifugation,
washing, recentrifugation, and resuspension of the
mitochondria created approximately the following
conditions: exposure of the experimental group
mitochondria to the 2000 p.g/ml of cephaloridine for
approximately 15 mm, a subsequent 1:20 dilution of
this concentration, and a final total dilution of ap-
proximately 1:1600 [30].
The mitochondria exposed to 2000 tg/ml of the
antibiotic early in this isolation procedure show
some decrease in respiratory rates compared with
the controls (Table 2). The overall degree of inhibi-
tion, however, is not as severe or as consistent as
that seen when the same concentration of cephalori-
dine is added to normal mitochondria in the respira-
tory chamber. Only the state 3 rates with glutamate
and malate are significantly below control values.
Thus, it appears that the isolation procedure may
significantly dilute the effect of the drug on mito-
chondrial respiration and that the in vivo studies
(mitochondria isolated from drug-treated animals)
could result in an underestimate of the actual in situ
effect of cephaloridine.
Renal tubule suspensions. Further evaluation of
the effect of cephaloridine on respiration by the
mitochondrion in the intact cell was done in studies
of renal cortical tubules. Tubule suspensions were
prepared by the method of Burg and Orloff [34].
Rates of respiration were measured in the same
chamber and using the same units applied in studies
of isolated mitochondria.
The effect of cephaloridine on tubular cell respi-
ration was measured under three conditions (Table
3 [11]: (1) in vitro short-term exposure (5 to 10 mm)
to 2000 tg/ml of the antibiotic; (2) in vitro longer-
term exposure to the same concentration (in all me-
dia throughout the entire process of preparation of
the tubules, approximately 2 hours); and (3) in vivo
exposure by the s.c. injection of 400 mg/kg of ceph-
aloridine 2 hours before the animals were sacri-
ficed. The high drug concentration was used be-
cause cellular cephaloridine uptake is not nearly as
great in vitro as it is in vivo [23]. The large in vivo
dose was chosen because only some components of
mitochondrial respiration are reduced by 200 mg/kg
of cephaloridine, and we were not examining ADP-
dependent respiration solely or directly in the intact
cell.
These measurements in tubule cells provide pre-
liminary supportive evidence that cephaloridine
nephrotoxicity may be mediated at least partly
through an effect on mitochondrial respiration. The
lack of immediacy of inhibition of oxygen consump-
tion in renal tubules after in vitro exposure is of
note, and leads one to conclude that the in situ (in-
Table 3. Toxicity of cephaloridine to rabbit renal cortical
tubule suspensionsa
Protocol
Respiratory ratec
(experimental/control)
% P5
In vitro (5 to 10 mm,
2000 g/ml) 93 6 NS
In vitro (2 hr, 2000 g/ml) 65 10 <0.025
Invivo(2hr,400mg/kg) 53 4 <0.001
a Table is modified from Ref. 11. See text for details of pro-
tocol. Results are means sEM; N 5 animals in each group.
5Vs 100%
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tracellular) mitochondrion is in some way isolated
from the antibiotic transport pool. Longer term in
vitro exposure of tubules, however, provides evi-
dence that this isolation may not be maintained as
cephaloridine toxicity develops. We will return to
the respiratory inhibiting effects of the cephalospor-
ins later in this discussion.
Metabolite hypothesis
One possible reason for a delayed expression of
drug-induced cytotoxicity is the requirement for
transformation to a toxic metabolite. Such a re-
quirement has been suggested for cephaloridine.
McMurtry and Mitchell have reported that two in-
hibitors of cytochome P-450 oxidase activity, co-
baltous chloride and piperonyl butoxide, reduce the
liver or renal toxicity of several substituted thio-
phenes, including cephaloridine, in the mouse and
the rat [35]. They concluded that the hepatotoxicity
or nephrotoxicity of these compounds is mediated
by a highly reactive metabolite—an epoxide pro-
duced by P-450 oxidase modification of the thio-
phene ring. Because phenobarbital, which is a stim-
ulator of hepatic but not of renal oxidase activity,
does not increase cephaloridine nephrotoxicity, the
intrarenal formation of a toxic metabolite was pro-
posed [35, 36].
A reactive metabolite of cephaloridine was not
demonstrated, and one important concern about
this hypothesis was expressed. In a more thorough-
ly studied model of this type of metabolite-mediated
toxicity, that of acetaminophen [36], the metabolite
can be rendered harmless by intracellular gluta-
thione. Cell injury or death results only under con-
ditions in which this sulfhydryl compound is deplet-
ed [36, 37]. Cephaloridine, unlike the other sub-
stituted thiophenes studied, produces no reduction
of renal glutathione [37].
Cephaloglycin toxicity and transport
To determine the importance of the thiophene
ring, we examined the potential cytotoxicity of sev-
eral cephalosporins in the guinea pig. This species
was chosen for screening studies because it is rela-
tively sensitive to cephalosporin toxicity but is
small enough to permit the economic use of large
drug doses. Benzylpenicillin was also studied be-
cause of a previously expressed concern that the
guinea pig is unusually sensitive to the nephrotoxic-
ity of the penicillins and cephalosporins in general
[38].
As seen in Table 4, a comparable degree of proxi-
mal tubular cytotoxicity was seen with equal doses
Table 4. Nephrotoxicity of several antibiotics in the guinea pig
Proximal tubular necrosis'
Dosea
mg/kg
no. of animals
None Mild Moderate Severe
Chephaloridine +40 400 1 0 4 7
mg/kg probenecid 400 12 0 0 0
Cephalothin 800 4 0 0 0
Cefazolin 800 4 0 0 0
Cephapirin 800 4 0 0 0
Cephalexin 800 4 0 0 0
Cephaloglycin + 100 400 1 1 1 3
mg/kg probenecid 400 6 0 0 0
Benzylpenicillin 800 6 0 0 0
a Injected S.C. 48 hours before sacrifice.
Scored as in Table 1
of cephaloridine and cephaloglycin but not with sig-
nificantly larger doses of the other cephalosporins
or of benzylpenicillin. We did not study the very
large doses of cefazolin that produce tubular necro-
sis in the rabbit [7, 10].
The finding of a comparable degree of nephrotox-
icity of cephaloglycin and cephaloridine has impor-
tant implications. It indicates that significant neph-
rotoxicity is not an unusual feature of an unusual
cephalosporin. Instead, we have two highly toxic
cephalosporins and two known to be mildly toxic in
the rabbit (cefazolin [7, 10] and cefamandole [8]).
All four drugs cause a proximal tubular necrosis [6-
8, 10, 15]. Probenecid has been studied with the first
three and has been found to protect against each
[10, 14, 18].
Cephalothin, which has a thiophene side-ring
(Fig. 2), is nearly nontoxic [21]. Cephaloridine,
which has the same side-ring, is highly toxic [7, 21].
Cephalexin, which has a phenylglycyl radical group
substitution, is relatively nontoxic [38]. Cephalogly-
cm, which has the same radical group, is highly tox-
ic. Cephaloglycin and cephaloridine do not share
the R' radical group substitution. Cefazolin and
cefamandole (not shown here) share no radical
group with one another or with the two more toxic
cephalosporins [5]. The common denominator in
the nephrotoxicity of the cephalosporins must
therefore involve the core structure to a great ex-
tent and cannot be simply equated to their radical
group substitutions.
We have in cephaloglycin another cephalosporin
for the further testing of the hypothesis that the
nephrotoxicity of this family of antibiotics may re-
late to the accumulation of unusually large or
trapped pools of intracellular drug, and for the fur-
ther investigation of the molecular basis of ceph-
alosporin toxicity.
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those of cephaloridine (P <0.001 in both cases) and
are not significantly different from those of the non-
toxic cephalexin. In further contrast to cephalori-
Cephalothin dine, the cortical concentrations of which remain
substantial 3 hours after injection, cortical concen-
trations of cephaloglycin have diminished signifi-
cantly by 2 hours (P < 0.05). In keeping with the
occurrence of active secretion of cephaloglycin and
cephalexin into the urine by the organic anion trans-
port system [5], the cortical concentrations and the
disappearance of these two drugs from renal cortex
are more like those of PAH than those of the rela-
tively trapped cephaloridine [19, 20, 25].
Differences between the toxicity of cephaloridine
and cephaloglycin. Electron microscopic examina-
tion of the lesion produced by cephaloglycin is cur-
rently being done by Dr. Fred Silverblatt at the
U.C.L.A. -Sepulveda Veterans Administration
Hospital. The results are too preliminary for de-
tailed description, but the changes in mitochondrial
configuration appear essentially the same as those
produced by cephaloridine.
Even if cephaloridine and cephaloglycin are cyto-
toxic through a related molecular event, certain fun-
damental differences in their action must exist. Be-
cause the cortical concentration of cephaloglycin is
lower and more transient than that of cephaloridine,
cephaloglycin must act more quickly on or cause a
more irreversible insult to the target receptor than
does cephaloridine, or it must bind more firmly to
the receptor. We have obtained the following evi-
dence that such differences between the two ceph-
alosporins exist:
First, as seen in Table 6, both are equally toxic to
guinea pigs when given in single doses. Cephalogly-
cm, however, shows a striking cumulative toxicity
when given in a series of single daily nontoxic
TableS. Renal cortical concentration of cephalosporins in the guinea pjga
Cephaloridine Cephaloglycin Cephalexin
Cortical concentration, p.g/g
AtO.Shr 3123 63 1364 154 1276 186
At2hr 933 89 513 109
At3hr 3576 148 — —
Serum concentration, g/ml
AtO.5hr 454 12 564 86 433 91
At2hr — 254 34 89 13
At3hr 206 4 — —
C/S ratio
At 0.5 hr 6.9 0.2 2.5 0.2 3.3 0.6
At2hr — 3.8 0.3 5.5 0.6
At3hr 17.2 0.7 — —
a The cephalosporins were given at the designated time before sacrifice (400 mg/kg, s.c.). Results are means SEM; N = 6 animals in
each group.
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Fig. 2. Chemical structures of several cephalosporin antibiotics.
Figure is modified from Moellering and Swartz [39].
Cortical concentrations. Measurements in guinea
pigs of the in situ cortical concentrations of ceph-
aloglycin and cephalexin are presented in Table 5,
along with previously published data obtained with
cephaloridine [19]. All animals received 400 mg/kg,
s.c., of the respective cephalosporin 0.5 to 3.0
hours before sacrifice. Cephaloglycin and its major
metabolite, desacetylcephaloglycin [40], are mea-
sured with equal reactivity by our fluorimetric as-
say; the total pool will presently be referred to sim-
ply as cephaloglycin.
The cortical concentrations and C/S ratios of
cephaloglycin at 0.5 hour are one half to one third of
Cefazol in
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Table 6. Single dose and cumulative nephrotoxicity of cephaloridine and cephaloglycin in the guinea piga
Proximal tubular necrosisb
no. of animals
None Mild Moderate Severe
Cephaloridine
400mgIkgxl 1 3 2 2
320mg/kgX5 5 0 0 1
240mg/kgxS 6 0 0 0
Cephaloglycin
400mg/kgxl 3 0 2 3
200mg/kgxI 6 0 0 0
240mg/kgx5 0 1 1 4
l6OmgIkgx5 3 1 0 2
200 mg/kg x 3
No probenecid
Probenecid, 100 mg/kg x 3
2
6
4
0
0
0
0
0
a Single s.c. dose was given for 1 day or 3 to 5 consecutive days; sacrifice was at 48 hours after the last dose.
Scored as in Table 1
doses, possibly because of an irreversible com-
ponent of binding or damage at the molecular level.
Even though cephaloridine is the more slowly ex-
creted of the two drugs [5], its cumulative toxicity is
minimal, as has also been noted in other laborato-
ries [21, 41].
Second, cephaloglycin toxicity to mitochondrial
respiration with succinate as substrate is approxi-
mately twice that of cephaloridie in vitro (Table 7).
Cephaloglycin, 1000 tgIml, reduces the state 3 rate
and the RCR by approximately as much as does
2000 g/ml of cephaloridine. Both the control and
the cephaloridine-inhibited rates in these more re-
cent studies are higher than those noted earlier [11,
30], possibly as a result of improved technique. The
respiratory toxic effects of both cephalosporins are,
however, qualitatively the same as previously seen
with cephaloridine [30].
Finally, we are able to demonstrate a degree of
toxicity to mitochondria after in vivo exposure to
cephaloglycin that has not been possible with ceph-
aloridine. Table 8 shows the results of studies of
mitochondria from control rabbits and from animals
that received 300 mg/kg of cephaloridine or 200 mgI
kg of cephaloglycin (doses of equivalent toxicity in
this species) 1 hour before sacrifice.
Although severe toxicity was seen in mito-
chondria from two of seven animals that received
cephaloridine, a significant toxic effect for the entire
group is seen at this early time only with the respira-
tory control ratio with succinate. In contrast, ceph-
aloglycin results in a substantial reduction of both
measures of respiration with both substrate groups.
The equivalent mitochondrial toxicity of ceph-
aloglycin with in vivo and in vitro exposure is nota-
Table 7. Comparative in vitro toxicity of cephaloridine and
cephaloglycin to rabbit renal cortical mitochondriaa
Succinatesubstrate
State 3 Respiratory
rated control ratio
Cephaloridine, 2000 gIm15
Control 104 17 3.2 0.3
Experimental (EIC) 51 6%e 55 8%e
Cephaloglycin, 1000 tg/mlc
Control 105 7 3.1 0.2
Experimental (E/C) 51 4%e 49 4%
a Results are means SEM.
b N = 7 animals.
N = 6 animals.
d Microatom equivalents oxygen consumed per minute per
gram of protein
P < 0.001 for E/C vs. 100%; NS for cephaloridine vs ceph-
aloglin for both measurements.
Table8. In vivo toxicity of cephaloridine and cephaloglycin to
rabbit renal cortical mitochondriaa
Substrate
State 3
rateb
Respiratory
control ratio
Controls
Glutamate-malate (8) 40 2 4.8 0.4
Succinate(l4) 92 7 3.2 0.2
Cephaloridine, 300mg/kg
Glutamate-malate (7) 30 9 4.2 0.9z
Succinate (7) 62 22C 2.4 03d
Cephaloglycin, 200mg/kg
Glutamate-malate(7) 9 3 1.6 0.3
Succinate(7) 25 12 1.4 0.3
a See text for details. Results are means SEM. Numbers in
parentheses denote the numbers of animals.
b Microatom equivalents oxygen consumed per minute per
gram of protein
NS, experimental vs. control.
p < 0.05, experimental vs. control.
ep < 0.001, experimental vs. control.
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bly different from the pattern previously noted with
cephaloridine (Table 2). If the partial reversibility of
cephaloridine toxicity by the mitochondrial isola-
tion process (Table 2) accounts for its lower mea-
sured in vivo toxicity compared with that seen in
vitro, then the more easily demonstrated in vivo
toxicity of cephaloglycin may be taken as further
evidence for the existence of an irreversible com-
ponent of the damaging effect of the latter ceph-
alosporin. More importantly, the results of the in
vivo studies with cephaloglycin provide new evi-
dence of the importance of the toxicity of the ceph-
alosporins to mitochondrial respiration in situ.
The timing of the studies shown in Table 8 coin-
cides with the earliest demonstrated cytotoxic
changes resulting from cephaloridine [15], at which
time no structural changes in tubular cell mito-
chondria are noted with either cephalosporin. Pre-
liminary studies with the nontoxic cephalexin show
no significant in vivo mitochondrial inhibitory effect
with succinate as substrate (unpublished). Although
further studies will be needed to document a cause-
and-effect relationship between the respiratory and
the proximal tubular toxicity of the cephalosporins,
the data presented above provide new evidence in
support of this hypothesis.
Clinical implications
The nephrotoxicity of cephaloridine in humans
has limited its use significantly [1, 5,9]. The toxicity
of cephaloglycin is presumably a reason for its
being released only for oral administration; the clin-
ical use of this cephalosporin has been very limited
[1, 5]. Massive infusions of cephalothin have been
reported to cause acute tubular necrosis in humans
[4], and it is possible that this complication devel-
oped because of the establishment of high and sus-
tained intracellular antibiotic concentrations. Ce-
fazolin [4] and cefamandole [42, 43] have not pre-
sented obvious problems of nephrotoxicity in
clinical trials. Because of this experience and their
low degree of toxicity even in the rabbit [7, 8, 10],
there has been no restriction of the use of these
newer cephalosporins in proper doses (modified
where prerenal azotemia or renal insufficiency ex-
ist) and where specifically indicated.
An area of important concern is the question of
additive toxicity of cephalosporins and amino-
glycosides. Evidence has been presented for [44-
47] and against [46, 48] such an interaction in sur-
veys of human use. Studies in rat [27, 49—51] and
the rabbit [52] have not provided evidence of addi-
tive toxicity. We must remain cautious, however, in
extending conclusions reached from these animal
studies of this drug interaction to the clinical set-
ting. Large differences in sensitivity to the nephro-
toxicity of antibiotics are seen between various spe-
cies. For example, rats are unusually resistant to
the cephalosporins [6, 7, 12], in contrast to rabbits,
guinea pigs, monkeys, and probably humans [6, 7,
9]. Rabbits are relatively resistant to amino-
glycosides [52] compared with rats [27, 49—51] and
humans [44—481.
The animal studies done so far may therefore be
inadequate for application to clinical use. No tox-
icity was seen in cephalosporin control groups in
the several studies of combined antibiotic adminis-
tration in rats [27, 49—5 1]. Some degree of toxicity
was seen with the aminoglycoside and the ceph-
alosporin in single-drug control groups in the stud-
ies done in this laboratory with rabbits [52]. We had
not yet begun to work with cephaloglycin, however,
and cephaloridine was the only cephalosporin test-
ed. Aminoglycoside toxicity is cumulative [53, 54],
whereas that of cephaloridine is not. The striking
difference between the cumulative cytotoxic effects
of cephaloridine and cephaloglycin (Table 6) leads
us to conclude that further study of the toxic inter-
action of aminoglycosides and various cephalospo-
rins is necessary both in humans and in laboratory
animals that are sensitive to both groups of drugs.
An understanding of the basic mechanisms of
toxicity of these antibiotics should be pursued to
permit the recognition and manipulation in appro-
priate animal models of circumstances that could
augment or diminish their individual and potentially
additive insult to the kidney in human use.
Summary. Certain members of the cephalosporin
group of antibiotics have the potential for producing
acute proximal tubular necrosis. This renal toxicity
is a potential problem with cephaloridine in the
therapeutic dose range. Although cefazolin and
cefamandole have no documented significant neph-
rotoxicity in human use, very large doses of these
cephalosporins produce the same lesion in laborato-
ry animals as does cephaloridine. The striking tox-
icity of cephaloridine is closely related to unusually
high cortical antibiotic concentrations. Several lines
of evidence have been presented that these high
concentrations are the result of a relative restriction
of movement of cephaloridine into the luminal fluid
after its active transport into the proximal tubular
cell at the antiluminal side. Evidence is presented
here that cephaloridine toxicity is at least partly me-
diated by an inhibitory effect on tubular cell mito-
chondrial respiration.
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Recent studies with cephaloglycin, a cephalospo-
nfl released only for oral administration, have
shown it to be at least as toxic as cephaloridine in
rabbits and guinea pigs. Cortical concentrations of
cephaloglycin, however, are much lower than those
of cephaloridine and are no higher than those of the
nontoxic cephalexin. In further contrast, the pro-
longed intracellular trapping seen with cephalori-
dine does not occur with cephaloglycin. Preliminary
evidence is discussed that lends support to the hy-
pothesis that cephaloridine may act as a relatively
reversible toxin at the intracellular level, with tubu-
lar necrosis resulting from persistent and high local
concentrations, and further that the molecular tox-
icity of cephaloglycin is greater and/or more irre-
versible, resulting in necrosis after the more tran-
sient occurrence of lower intracellular concentra-
tions.
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